Aussie stem cell company Regeneus out-licenses Progenza to Kyocera for Japan market

Biotechnology and biopharmaceutical industry publication, BioWorld, also covered the news on Regeneus out-licensing its lead mesenchymal stem cell (MSC) and Secretome therapy, Progenza, to Japan’s Kyocera Corporation for osteoarthritis of the knee for the Japan market, The report noted Kyocera has a strong presence among, and relationships with, physicians who treat osteoarthritis, and that this would help Progenza in the long term.

Read the full article here.

Regeneus, Kyocera ink $19M deal for knee osteoarthritis treatment

Bio and Health Sciences publication BioSpectrum covered Regeneus' deal with Kyocera for Progenza OA in Japan in their Asia Edition.

Read the full article in BioSpectrum Asia here.